

ORAL PRESENTATION

Open Access

CTLA-4 checkpoint blockade in breast cancer, a case in point report

Chiara Dellepiane^{1*}, Michela Lia², Mario Roberto Sertoli¹

From Breast Cancer Immunotherapy Symposium (BRECIS), part of the Sidra Symposia Series, held in partnership with the Society for Immunotherapy of Cancer Doha, Qatar. 13-14 April 2015

A patient concomitantly affected by breast cancer and melanoma is presented in order to contribute to the ongoing debate on breast cancer immunotherapy [1,2]. In 1996 the patient was operated on for left early breast cancer and treated with adjuvant radiotherapy and 5 years Tamoxifen. In 2009 biochemical progression and bone metastases appeared so Letrozole hormonal therapy was carried out, ensuing in clinical stabilization. In 2010, a left arm cutaneous melanoma was excised (pT4a Breslow 4.5 mm), and axillary nodal dissection detecting an involved node. Because of subsequent in-transit metastases, the patient underwent chemotherapy hyperthermic perfusion, reaching a dermic complete response (CR). Suddenly melanoma progressed in the lung and liver, as confirmed by ultrasound driven biopsy. Chemotherapy (DTIC) was given, achieving visceral partial response. At this point Ipilimumab [3] was available and CR of liver, lung, and dermic metastases was obtained after 4 cycles, while bone lesions remained stable and considered breast cancer. Four months later novel liver metastases appeared and biopsy unexpectedly confirmed their breast cancer origin. The patient after unsuccessful chemotherapy, finally died of liver failure, without evidence of melanoma metastases. This very special case shows the impressive discrepancy in response to CTLA4 check-point therapy between melanoma and breast cancer.

Authors' details

¹Clinic of Medical Oncology, IRCCS SAN MARTINO IST, Genoa University, Genoa, Italy. ²EORTC, Bruxelles, Belgium.

¹Clinic of Medical Oncology, IRCCS SAN MARTINO IST, Genoa University, Genoa, Italy

Full list of author information is available at the end of the article



© 2015 Dellepiane et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Published: 14 August 2015

References

1. Emens LA: LA Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. *Expert Rev Anticancer Ther* 2012, **12**(12):1597-611, doi: 10.1586/era.12.147. Review.
2. Nanda R, Chow LQ, Dees EC, et al: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. *SABCS 2014* San Antonio, Texas; 2014, Abstract S1-09.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010, **363**:711-723.

doi:10.1186/2051-1426-3-S1-O4

Cite this article as: Dellepiane et al: CTLA-4 checkpoint blockade in breast cancer, a case in point report. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 1):O4.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

